Xalatan to delay glaucoma in patients with increased intraocular pressure

Published: 2002-06-21 06:58:00

Updated: 2002-06-21 06:58:00

The reduction in intraocular pressure (IOP) is associated with far less risk of inducing glaucoma, which may cause blindness and loss of vision, according to a 5-year AccorOcular Hypertension Treatment Study (OHTS) of the U.S. National Ophthalmology Institute conducted by 22 hospitals in diverse ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK